We claim:

1. An immunostimulatory composition comprising:
at least one oligonucleotide comprising both an RNA region and a DNA region, wherein at least one terminus of the oligonucleotide comprises RNA.

2. The composition of claim 1, wherein the DNA region comprises at least one unmethylated CpG dinucleotide.

3. The composition of claim 2, wherein the DNA region comprises at least one CpG sequence.

4. The composition of claim 2, wherein both termini comprise at least 1 RNA nucleotide.

5. The composition of claim 3, wherein at least one terminus comprises poly A RNA.

6. The composition of claim 1, wherein a linkage between at least two nucleotides of the oligonucleotide comprises a modification of the phosphate backbone.

7. The composition of claim 6, wherein the modification is a phosphorathioate modification.

8. An immunostimulatory composition comprising at least a first oligonucleotide and a second oligonucleotide, wherein both the first and second oligonucleotides each contain at least one RNA region and at least one DNA region, wherein at least one terminus of each oligonucleotide comprises RNA.

9. The immunostimulatory composition of claim 8, wherein each oligonucleotide elicits a different immune stimulation profile

10. An adjuvant comprising at least one oligonucleotide comprising both an RNA region and a DNA region, wherein at least one terminus of the oligonucleotide comprises RNA.

11. A vaccine comprising:
at least one oligonucleotide comprising both an RNA region and a DNA region, wherein at least one terminus of the oligonucleotide comprises RNA, and wherein said oligonucleotide is associated with a physiological carrier or delivery system.

12. A method of stimulating innate immunity comprising:
administering at least one oligonucleotide comprising both an RNA region and a DNA region, wherein at least one terminus of the oligonucleotide comprises RNA, and wherein said oligonucleotide is associated with a physiological carrier or delivery system.

13. A method of stimulating global immunity comprising:
administering at least one oligonucleotide comprising both an RNA region and a DNA region, wherein at least one terminus of the oligonucleotide comprises RNA, and wherein said oligonucleotide is associated with a physiological carrier or delivery system.

14. A vaccine comprising:
1) at least one oligonucleotide comprising both an RNA region and a DNA region, wherein at least one terminus of the oligonucleotide comprises RNA and,
2) at least one target antigen.

15. A method of stimulating a cellular immune response comprising:
administrating
1) at least one oligonucleotide comprising both an RNA region and a DNA region, wherein at least one terminus of the oligonucleotide comprises RNA and,
2) at least one target antigen.

16. A method of stimulating a humoral immune response comprising:
administrating
1) at least one oligonucleotide comprising both an RNA region and a DNA region, wherein at least one terminus of the oligonucleotide comprises RNA and,
2) at least one target antigen.

17. A method of making a vaccine comprising:
associating
1) at least one oligonucleotide comprising both an RNA region and a DNA region, wherein at least one terminus of the oligonucleotide comprises RNA, and
2) a physiological carrier or delivery system.